Application of Population Pharmacokinetic-Pharmacodynamic Approaches in the Design of Translational Strategies for Development of Antibody-Based Therapeutics

作者: Feng Jin

DOI: 10.1007/978-1-4419-5955-3_12

关键词:

摘要: Population-based pharmacokinetic-pharmacodynamic (PK-PD) approaches have been successfully applied in various stages of drug development over the last few decades. The antibody-based therapeutics has benefited substantially from utilization population approaches. Moreover, almost all FDA-approved monoclonal antibody evaluated using In this chapter, application PK-PD methods will be reviewed context translational strategies employed during therapeutics.

参考文章(61)
Y Zhang, L Zhang, S Abraham, S Apparaju, T-C Wu, JM Strong, S Xiao, AJ Atkinson Jr, KE Thummel, JS Leeder, C Lee, GJ Burckart, LJ Lesko, S-M Huang, Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications Clinical Pharmacology & Therapeutics. ,vol. 85, pp. 305- 311 ,(2009) , 10.1038/CLPT.2008.208
Céline Dartois, Gilles Freyer, Mauricette Michallet, Emilie Hénin, Benoît You, Isabelle Darlavoix, Claudine Vermot-Desroches, Brigitte Tranchand, Pascal Girard, None, Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease. Clinical Pharmacokinectics. ,vol. 46, pp. 417- 432 ,(2007) , 10.2165/00003088-200746050-00004
Chee M. Ng, Amita Joshi, Russell L. Dedrick, Marvin R. Garovoy, Robert J. Bauer, Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis Pharmaceutical Research. ,vol. 22, pp. 1088- 1100 ,(2005) , 10.1007/S11095-005-5642-4
Raymond G. Slavin, Caterina Ferioli, Stacey J. Tannenbaum, Carmen Martin, Martin Blogg, Philip J. Lowe, Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Journal of Allergy and Clinical Immunology. ,vol. 123, pp. 107- 113.e3 ,(2009) , 10.1016/J.JACI.2008.09.050
Zhenhua Xu, Kathleen Seitz, Adedigbo Fasanmade, Joyce Ford, Paul Williamson, Weichun Xu, Hugh M. Davis, Honghui Zhou, Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis The Journal of Clinical Pharmacology. ,vol. 48, pp. 681- 695 ,(2008) , 10.1177/0091270008316886
France Mentré, Roberto Gomeni, A Two-Step Iterative Algorithm For Estimation In Nonlinear Mixed-Effect Models With An Evaluation In Population Pharmacokinetics Journal of Biopharmaceutical Statistics. ,vol. 5, pp. 141- 158 ,(1995) , 10.1080/10543409508835104
Adedigbo A. Fasanmade, Omoniyi J. Adedokun, Joyce Ford, Danika Hernandez, Jewel Johanns, Chuanpu Hu, Hugh M. Davis, Honghui Zhou, Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis European Journal of Clinical Pharmacology. ,vol. 65, pp. 1211- 1228 ,(2009) , 10.1007/S00228-009-0718-4
Nicolas Frey, Susan Grange, Thasia Woodworth, Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. The Journal of Clinical Pharmacology. ,vol. 50, pp. 754- 766 ,(2010) , 10.1177/0091270009350623
Honghui Zhou, Chuanpu Hu, Yaowei Zhu, Ming Lu, Sam Liao, Newman Yeilding, Hugh M. Davis, Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. The Journal of Clinical Pharmacology. ,vol. 50, pp. 257- 267 ,(2010) , 10.1177/0091270009343695
Ene I. Ette, He Sun, Thomas M. Ludden, Balanced Designs in Longitudinal Population Pharmacokinetic Studies The Journal of Clinical Pharmacology. ,vol. 38, pp. 417- 423 ,(1998) , 10.1002/J.1552-4604.1998.TB04446.X